Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Yazdanpanah, Omid
Benjamin, David Joseph
Vosoughi, Elham
Raad, Ali
Popal, Medina
Kongtim, Piyanuch
Mar, Nataliya
Rezazadeh, Arash
机构：
[1] Univ Calif Irvine, Div Hematol Oncol, Orange, CA 92668 USA
[2] Hoag Family Canc Inst, Newport Beach, CA USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Chao Comprehens Canc Ctr, Stern Ctr Canc Clin Trials & Res, Orange, CA USA
[5] Univ Calif Irvine, Orange, CA 92668 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16530
引用
收藏
页数：1
相关论文
共 50 条
  • [21] GAINING AN UNDERSTANDING OF ALTERNATIVE DOSING SCHEDULES AS AN APPROACH TO ADVERSE EVENT MANAGEMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS RECEIVING SUNITINIB.
    Ryan, Joanne C.
    Clair, Andrew G.
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [22] Patient preferences for metastatic renal cell carcinoma treatments: a discrete-choice experiment
    Gonzalez, Juan M.
    Doan, Justin
    Gebben, David J.
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 22 - 23
  • [23] Metastatic Renal Cell Carcinoma Management
    Heldwein, Flavio L.
    Escudier, Bernard
    Smyth, Gordon
    Souto, Carlos A. V.
    Vallancien, Guy
    INTERNATIONAL BRAZ J UROL, 2009, 35 (03): : 256 - 270
  • [24] Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)
    Prati, Veronica
    Ortega, Cinzia
    Ballatore, Valentina
    Galizia, Danilo
    Ruatta, Fiorella
    Bonzano, Alessandro
    Aliberti, Sandra
    Grignani, Giovanni
    Aglietta, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC)
    Haddad, Housam
    Rini, Brian I.
    Jonasch, Eric
    Tannir, Nizar M.
    Dreicer, Robert
    Garcia, Jorge A.
    Wood, Laura S.
    Elson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Factors affecting treatment trends for metastatic renal cell carcinoma (mRCC) in Australia
    Liow, Elizabeth
    Wong, Shirley
    Weickhardt, Andrew
    Davis, Ian D.
    Shapiro, Jeremy
    Parnis, Francis
    Crumbaker, Megan
    Pranavan, Ganes
    Hocking, Christopher
    Azad, Arun
    Anton, Angelyn
    Spain, Lavinia
    Gibbs, Peter
    Tran, Ben
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 71 - 71
  • [27] Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
    Tracz, Amanda
    Mastri, Michalis
    Lee, Christina R.
    Pili, Roberto
    Ebos, John M. L.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2014, (86):
  • [28] Looking for predictive biomarkers for sunitinib in metastatic renal clear cell carcinoma (mRCC)
    Maroto, P.
    Esteban, E.
    Méndez-Vidal, M. J.
    Fernandez-Parra, E. M.
    Leon, L.
    Perez-Valderrama, B.
    Domenech, M.
    Calderero, V.
    Perez-Gracia, J. L.
    Algaba, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S676 - S676
  • [29] Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
    Houk, B. E.
    Amantea, M.
    Motzer, R. J.
    Michaelson, M. D.
    Rini, B. I.
    George, D. J.
    Redman, B. G.
    Hudes, G. R.
    Poland, B.
    Bello, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [30] Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).
    Lalani, Aly-Khan A.
    Xie, Wanling
    Lin, Xun
    Steinharter, John A.
    Martini, Dylan J.
    Duquette, Audrey
    Bosse, Dominick
    McKay, Rana R.
    Simantov, Ronit
    Wei, Xiao X.
    McGregor, Bradley A.
    Harshman, Lauren Christine
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345